Johnny Mahlangu to Humans
This is a "connection" page, showing publications Johnny Mahlangu has written about Humans.
Connection Strength
3,239
-
Extension Study With rVIII-SingleChain in Previously Untreated Patients (PUPs) With Severe Haemophilia A. Haemophilia. 2025 Mar; 31(2):214-223.
Score: 0,074
-
Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies. Expert Rev Hematol. 2024 Oct; 17(10):741-748.
Score: 0,072
-
Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A. J Thromb Haemost. 2024 Jul; 22(7):1880-1893.
Score: 0,070
-
Diagnosis and treatment challenges in lower resource countries: State-of-the-art. Haemophilia. 2024 Apr; 30 Suppl 3:78-85.
Score: 0,069
-
Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. N Engl J Med. 2023 02 23; 388(8):694-705.
Score: 0,064
-
Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results. Br J Haematol. 2023 01; 200(2):240-248.
Score: 0,063
-
Underdiagnosis of iron deficiency anaemia in HIV-infected individuals: a pilot study using soluble transferrin receptors and intensive bone marrow iron stores to improve the diagnosis. J Clin Pathol. 2023 Aug; 76(8):555-560.
Score: 0,063
-
A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia. Br J Haematol. 2023 01; 200(2):229-239.
Score: 0,062
-
Prophylaxis is the new standard of care in patients with haemophilia. S Afr Med J. 2022 05 31; 112(6):405-408.
Score: 0,061
-
Emicizumab state-of-the-art update. Haemophilia. 2022 May; 28 Suppl 4:103-110.
Score: 0,061
-
An update of the current pharmacotherapeutic armamentarium for hemophilia A. Expert Opin Pharmacother. 2022 Jan; 23(1):129-138.
Score: 0,058
-
Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B. Haemophilia. 2021 Jul; 27(4):574-580.
Score: 0,057
-
Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors. Haemophilia. 2021 Mar; 27(2):221-228.
Score: 0,056
-
Immunoglobulin subtyping and quantification in direct antiglobulin test: positive haemolysis in an HIV-prevalent setting. J Clin Pathol. 2022 Feb; 75(2):117-120.
Score: 0,055
-
Redefining prophylaxis in the modern era. Haemophilia. 2021 Feb; 27 Suppl 3:21-27.
Score: 0,053
-
Requirements to participate in haemophilia clinical trials. Haemophilia. 2020 Apr; 26 Suppl 3:22-25.
Score: 0,053
-
BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for =2 years. Eur J Haematol. 2020 Jun; 104(6):594-601.
Score: 0,053
-
Capacity building for inherited bleeding disorders in sub-Saharan Africa. Blood Adv. 2019 12 06; 3(Suppl 1):5-7.
Score: 0,051
-
Home therapy for inherited bleeding disorders in South Africa: Results of a modified Delphi consensus process. S Afr Med J. 2019 Aug 28; 109(9):639-644.
Score: 0,051
-
Emicizumab for the prevention of bleeds in hemophilia A. Expert Opin Biol Ther. 2019 08; 19(8):753-761.
Score: 0,050
-
Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS). Haemophilia. 2019 May; 25(3):382-391.
Score: 0,049
-
Analytical Performance of a New Immunoturbidimetric Assay for von Willebrand Factor (VWF) Activity Testing. Clin Lab. 2019 Apr 01; 65(4).
Score: 0,049
-
Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting. Haemophilia. 2019 Mar; 25(2):213-220.
Score: 0,049
-
Thrombotic thrombocytopenic purpura: A 5-year tertiary care centre experience. J Clin Apher. 2019 Feb; 34(1):44-50.
Score: 0,048
-
rFVIIIFC for hemophilia A prophylaxis. Expert Rev Hematol. 2018 12; 11(12):937-943.
Score: 0,048
-
Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors. BioDrugs. 2018 Dec; 32(6):561-570.
Score: 0,048
-
Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study. Haemophilia. 2018 Nov; 24(6):921-929.
Score: 0,048
-
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018 08 30; 379(9):811-822.
Score: 0,047
-
Emerging therapies for haemophilia - Global perspective. Haemophilia. 2018 May; 24 Suppl 6:15-21.
Score: 0,046
-
Defining extended half-life rFVIII-A critical review of the evidence. Haemophilia. 2018 May; 24(3):348-358.
Score: 0,046
-
The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from the ADEPT2 trial. Blood Coagul Fibrinolysis. 2017 Apr; 28(3):224-229.
Score: 0,043
-
Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors. Haemophilia. 2017 Jan; 23(1):33-41.
Score: 0,041
-
TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity. Haemophilia. 2016 Nov; 22(6):873-879.
Score: 0,041
-
Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX. Haemophilia. 2017 Jan; 23(1):67-76.
Score: 0,041
-
Extended half-life clotting factor concentrates: results from published clinical trials. Haemophilia. 2016 Jul; 22 Suppl 5:25-30.
Score: 0,041
-
Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. Blood. 2016 08 04; 128(5):630-7.
Score: 0,041
-
Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thromb Haemost. 2016 07 04; 116(1):1-8.
Score: 0,040
-
Diagnosis of iron deficiency anaemia in hospital patients: Use of the reticulocyte haemoglobin content to differentiate iron deficiency anaemia from anaemia of chronic disease. S Afr Med J. 2015 Nov 20; 106(1):53-4.
Score: 0,039
-
Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity. J Thromb Haemost. 2015 Nov; 13(11):1989-98.
Score: 0,039
-
Uptake of Genetic Counseling, Knowledge of Bleeding risks and Psychosocial Impact in a South African Cohort of Female Relatives of People with Hemophilia. J Genet Couns. 2015 Dec; 24(6):978-86.
Score: 0,037
-
Assessment of outcomes. Haemophilia. 2014 May; 20 Suppl 4:114-20.
Score: 0,035
-
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014 Jan 16; 123(3):317-25.
Score: 0,034
-
Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia. J Thromb Haemost. 2012 May; 10(5):773-80.
Score: 0,030
-
Haemophilia care in South Africa: 2004-2007 look back. Haemophilia. 2009 Jan; 15(1):135-41.
Score: 0,024
-
Guideline for the treatment of haemophilia in South Africa. S Afr Med J. 2008 Feb; 98(2 Pt 2):126-40.
Score: 0,023
-
Three-way comparison of methods for the measurement of the erythrocyte sedimentation rate. J Clin Lab Anal. 2008; 22(5):346-52.
Score: 0,023
-
Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors. Haemophilia. 2025 Jan; 31(1):78-86.
Score: 0,018
-
The translational gap for gene therapies in low- and middle-income countries. Sci Transl Med. 2024 May 08; 16(746):eadn1902.
Score: 0,017
-
Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective. Haemophilia. 2024 Mar; 30(2):257-266.
Score: 0,017
-
Recommendations for a minimum data set for monitoring gene therapy in hemophilia: communication from the ISTH SSC Working Group on Gene Therapy. J Thromb Haemost. 2024 May; 22(5):1510-1515.
Score: 0,017
-
FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic. J Thromb Haemost. 2024 Apr; 22(4):990-1000.
Score: 0,017
-
Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1. J Thromb Haemost. 2023 12; 21(12):3450-3462.
Score: 0,017
-
Phase 3 Trial of Concizumab in Hemophilia with Inhibitors. N Engl J Med. 2023 Aug 31; 389(9):783-794.
Score: 0,017
-
Implementation of a gene therapy education initiative by the ASGCT and Muhimbili University of Health and Allied Sciences. Mol Ther. 2023 09 06; 31(9):2561-2565.
Score: 0,017
-
Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B. Blood Adv. 2023 07 11; 7(13):3049-3057.
Score: 0,017
-
RNA sequencing suggests that non-coding RNAs play a role in the development of acquired haemophilia. J Cell Mol Med. 2023 07; 27(13):1790-1796.
Score: 0,016
-
Reclassifying hemophilia to include the definition of outcomes and phenotype as new targets. J Thromb Haemost. 2023 07; 21(7):1737-1740.
Score: 0,016
-
Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. Lancet Haematol. 2023 Mar; 10(3):e168-e177.
Score: 0,016
-
World federation of hemophilia international hemophilia training fellowship program: 50 years of enhancing global care. Haemophilia. 2022 09; 28(5):S129-S131.
Score: 0,015
-
Haemophilia gene therapy-Update on new country initiatives. Haemophilia. 2022 May; 28 Suppl 4:61-67.
Score: 0,015
-
A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia. Blood. 2022 04 28; 139(17):2642-2652.
Score: 0,015
-
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. N Engl J Med. 2022 03 17; 386(11):1013-1025.
Score: 0,015
-
Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A. Hum Gene Ther. 2022 Apr; 33(7-8):432-441.
Score: 0,015
-
A cohort study of the relationship between anaemia, mean corpuscular volume and mortality among a CKD population in South Africa. Afr Health Sci. 2021 Dec; 21(4):1764-1775.
Score: 0,015
-
Unexplained hemorrhagic syndrome? Consider acquired hemophilia A or B. Blood Rev. 2022 05; 53:100907.
Score: 0,015
-
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia. 2021 Nov; 27(6):921-931.
Score: 0,015
-
Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies. Haemophilia. 2021 Nov; 27(6):e772-e775.
Score: 0,015
-
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors. Haemophilia. 2021 Nov; 27(6):911-920.
Score: 0,015
-
A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH. J Thromb Haemost. 2021 08; 19(8):1883-1887.
Score: 0,014
-
The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia. 2021 Sep; 27(5):854-865.
Score: 0,014
-
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021 04 22; 137(16):2231-2242.
Score: 0,014
-
Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study. Haemophilia. 2021 May; 27(3):398-407.
Score: 0,014
-
The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet. 2021 02 13; 397(10274):630-640.
Score: 0,014
-
Application of a hemophilia mortality framework to the Emicizumab Global Safety Database. J Thromb Haemost. 2021 01; 19 Suppl 1:32-41.
Score: 0,014
-
Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database. J Thromb Haemost. 2021 01; 19 Suppl 1:21-31.
Score: 0,014
-
Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. J Thromb Haemost. 2020 11; 18(11):3074-3077.
Score: 0,014
-
Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study. Haemophilia. 2020 Nov; 26(6):1009-1018.
Score: 0,014
-
Hepcidin and GDF-15 are potential biomarkers of iron deficiency anaemia in chronic kidney disease patients in South Africa. BMC Nephrol. 2020 09 29; 21(1):415.
Score: 0,014
-
Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study. Pediatr Blood Cancer. 2020 10; 67(10):e28474.
Score: 0,013
-
WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020 Aug; 26 Suppl 6:1-158.
Score: 0,013
-
The evolving landscape of gene therapy for congenital haemophilia: An unprecedented, problematic but promising opportunity for worldwide clinical studies. Blood Rev. 2021 03; 46:100737.
Score: 0,013
-
Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B-YOND extension study. Haemophilia. 2020 Nov; 26(6):e262-e271.
Score: 0,013
-
World Federation of Hemophilia Gene Therapy Registry. Haemophilia. 2020 Jul; 26(4):563-564.
Score: 0,013
-
Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. Haemophilia. 2020 May; 26(3):494-502.
Score: 0,013
-
Towards a global multidisciplinary consensus framework on haemophilia gene therapy: Report of the 2nd World Federation of Haemophilia Gene Therapy Round Table. Haemophilia. 2020 May; 26(3):443-449.
Score: 0,013
-
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019 12 12; 134(24):2127-2138.
Score: 0,013
-
Improving access to hemophilia care in sub-Saharan Africa by capacity building. Blood Adv. 2019 12 06; 3(Suppl 1):1-4.
Score: 0,013
-
Gene and cell therapy in South Africa: Current status and future prospects. S Afr Med J. 2019 Sep 10; 109(8b):12-16.
Score: 0,013
-
Patient blood management: A solution for South Africa. S Afr Med J. 2019 Jun 28; 109(7):471-476.
Score: 0,012
-
The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia. 2019 Jan; 25(1):33-44.
Score: 0,012
-
Utility of reticulocyte haemoglobin content and percentage hypochromic red cells as markers of iron deficiency anaemia among black CKD patients in South Africa. PLoS One. 2018; 13(10):e0204899.
Score: 0,012
-
Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigmâ„¢ trials. Haemophilia. 2018 Nov; 24(6):911-920.
Score: 0,012
-
The predictive value of factor VIII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH. J Thromb Haemost. 2018 10; 16(10):2106-2110.
Score: 0,012
-
Haemophilia clinical care and research needs: Assessing priorities. Haemophilia. 2018 07; 24(4):e270-e273.
Score: 0,012
-
Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII. Haemophilia. 2018 May; 24(3):376-384.
Score: 0,012
-
Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein. Haemophilia. 2018 Jan; 24(1):77-84.
Score: 0,011
-
Evaluation of the self-administered bleeding assessment tool (Self-BAT) in haemophilia carriers and correlations with quality of life. Haemophilia. 2017 11; 23(6):e536-e538.
Score: 0,011
-
Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017 08 31; 377(9):809-818.
Score: 0,011
-
Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A. Haemophilia. 2017 May; 23(3):392-399.
Score: 0,011
-
Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study. Lancet Haematol. 2017 Feb; 4(2):e75-e82.
Score: 0,011
-
Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. Thromb Haemost. 2017 02 28; 117(3):508-518.
Score: 0,010
-
Evaluation of the utility of the ISTH-BAT in haemophilia carriers: a multinational study. Haemophilia. 2016 Nov; 22(6):912-918.
Score: 0,010
-
Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia. 2016 Nov; 22(6):866-872.
Score: 0,010
-
Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery. Haemophilia. 2016 Jul; 22(4):e259-66.
Score: 0,010
-
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016 May 26; 374(21):2054-64.
Score: 0,010
-
Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigmâ„¢4). Thromb Res. 2016 May; 141:69-76.
Score: 0,010
-
Naturally occurring resistance mutations within the core and NS5B regions in hepatitis C genotypes, particularly genotype 5a, in South Africa. Antiviral Res. 2016 Mar; 127:90-8.
Score: 0,010
-
Optimising musculoskeletal care for patients with haemophilia. Eur J Haematol. 2015 Dec; 95 Suppl 81:11-21.
Score: 0,010
-
Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia. 2016 Jan; 22(1):72-80.
Score: 0,010
-
Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost. 2015 Jun; 13(6):967-77.
Score: 0,009
-
Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015 May; 13(5):743-54.
Score: 0,009
-
Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10-year survey. Haemophilia. 2015 Sep; 21(5):589-97.
Score: 0,009
-
Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J Thromb Haemost. 2014 Nov; 12(11):1788-800.
Score: 0,009
-
Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood. 2014 Dec 18; 124(26):3880-6.
Score: 0,009
-
Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study. Br J Haematol. 2015 Jan; 168(1):124-34.
Score: 0,009
-
Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. J Thromb Haemost. 2014 Aug; 12(8):1244-53.
Score: 0,009
-
Genetic factors influencing inhibitor development in a cohort of South African haemophilia A patients. Haemophilia. 2014 Sep; 20(5):687-92.
Score: 0,009
-
Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013 Dec 12; 369(24):2313-23.
Score: 0,008
-
Key issues in inhibitor management in patients with haemophilia. Blood Transfus. 2014 Jan; 12 Suppl 1:s319-29.
Score: 0,008
-
Guidelines for the management of hemophilia. Haemophilia. 2013 Jan; 19(1):e1-47.
Score: 0,008
-
Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost. 2012 Jan; 10(1):81-9.
Score: 0,007
-
Guidelines for the treatment of myelodysplastic syndromes (MDS) in South Africa. S Afr Med J. 2011 Nov 28; 101(12):900-6.
Score: 0,007
-
Haemophilia management: time to get personal? Haemophilia. 2011 Sep; 17(5):721-8.
Score: 0,007
-
Palindromic-nucleotide substitutions (PNS) of hepatitis C virus genotypes 1 and 5a from South Africa. J Virol Methods. 2011 Aug; 175(2):272-7.
Score: 0,007
-
Local reference ranges for full blood count and CD4 lymphocyte count testing. S Afr Med J. 2009 Apr; 99(4):243-8.
Score: 0,006
-
Hepatitis C virus genotypes in two different patient cohorts in Johannesburg, South Africa. Arch Virol. 2008; 153(11):2049-58.
Score: 0,006
-
Genotype-phenotype correlation in combined deficiency of factor V and factor VIII. Blood. 2008 Jun 15; 111(12):5592-600.
Score: 0,006
-
Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and multiple myeloma in South Africa. Diagn Mol Pathol. 2001 Jun; 10(2):95-9.
Score: 0,004